Food and Drug Administration Commissioner Marty Makary said he plans to review the safety of abortion drug mifepristone after a recent study raised concerns about medical side effects.

The US Food and Drug Administration will meet its drug approval targets this year despite cutting thousands of staff, the agency’s commissioner said.

A recent study found that 11 percent of women experience an adverse effect from mifepristone, 22 times higher than its current label indicates.